Literature DB >> 12222763

Formulation effects on ocular absorption of brimonidine in rabbit eyes.

Andrew A Acheampong1, David Small, Val Baumgarten, Devin Welty, Diane Tang-Liu.   

Abstract

Purite (stabilized oxychloro complex) and benzalkonium chloride (BAK) are preservatives. We investigated formulation effects on ocular absorption of brimonidine in rabbit eyes. The formulations compared were: Alphagan (0.2% brimonidine tartrate/0.005% BAK, pH 6.4), Brimonidine-Purite (0.2% brimonidine tartrate/0.005% Purite, pH 7.2), and Brimonidine-PF (0.2% brimonidine tartrate, preservative-free (PF), pH 6.4) solutions. The study was conducted in a cross-over fashion; albino rabbits (n = 18) were given a single 35 microl drop of each test formulation in each eye. Aqueous humor samples were collected at selected times post-dose from subgroups of 2 rabbits per timepoint and analyzed for brimonidine concentrations by LC-MS/MS. The AUC and Cmax were calculated. The results showed rapid ocular absorption of brimonidine, with peak concentrations at 0.33-1 hr. The AUC(0-5hr) values were 3.78 +/- 0.38, 2.77 +/- 0.22, and 2.49 +/- 0.22 microg-hr/ml (mean +/- SEM) for Brimonidine-Purite, Alphagan and Brimonidine-PF, respectively. The corresponding Cmax values were 2.69 +/- 0.72, 1.74 +/- 0.13, and 1.24 +/- 0.22 microg/ml (mean +/- SEM). Brimonidine-Purite provided significantly higher AUC(0-5hr) than Alphagan (p < 0.05). No statistical significant difference in AUC(0-5hr) was found between Alphagan and Brimonidine-PF. In conclusion, 0.2% Brimonidine-Purite was 1.4 and 1.5 times more ocularly bioavailable in rabbits than 0.2% Alphagan and 0.2% Brimonidine-PF, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12222763     DOI: 10.1089/10807680260218498

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  11 in total

Review 1.  Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations.

Authors:  Jie Shen; Guang Wei Lu; Patrick Hughes
Journal:  Pharm Res       Date:  2018-09-25       Impact factor: 4.200

Review 2.  Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes.

Authors:  Aniruddha Amrite; Vidya Pugazhenthi; Narayan Cheruvu; Uday Kompella
Journal:  Expert Opin Drug Deliv       Date:  2010-05       Impact factor: 6.648

3.  Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.

Authors:  Pradeep K Karla; Ravinder Earla; Sagar H Boddu; Thomas P Johnston; Dhananjay Pal; Ashim Mitra
Journal:  Curr Eye Res       Date:  2009-01       Impact factor: 2.424

Review 4.  Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

Authors:  Uday B Kompella; Aniruddha C Amrite; Rashmi Pacha Ravi; Shelley A Durazo
Journal:  Prog Retin Eye Res       Date:  2013-04-17       Impact factor: 21.198

5.  Effect of eye pigmentation on transscleral drug delivery.

Authors:  Narayan P S Cheruvu; Aniruddha C Amrite; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

6.  [Morphological alterations induced by preservatives in eye drops].

Authors:  K K Huber-van der Velden; H Thieme; M Eichhorn
Journal:  Ophthalmologe       Date:  2012-11       Impact factor: 1.059

Review 7.  Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma.

Authors:  Ryan G Strickland; Mary Anne Garner; Alecia K Gross; Christopher A Girkin
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

8.  28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres.

Authors:  Morgan V Fedorchak; Ian P Conner; Carlos A Medina; Jeremy B Wingard; Joel S Schuman; Steven R Little
Journal:  Exp Eye Res       Date:  2014-06-28       Impact factor: 3.467

9.  The management of glaucoma and intraocular hypertension: current approaches and recent advances.

Authors:  Robert J Noecker
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

10.  Ocular and Systemic Pharmacokinetics of Brimonidine and Timolol After Topical Administration in Rabbits: Comparison Between Fixed-Combination and Single Drugs.

Authors:  Gen Suzuki; Eriko Kunikane; Keisuke Shinno; Seiko Kozai; Masaaki Kurata; Akio Kawamura
Journal:  Ophthalmol Ther       Date:  2020-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.